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Background: Patients with end-stage renal disease (ESRD) have multiple comorbid conditions. Obtaining comorbidity
data from medical records is cumbersome. A self-report comorbidity questionnaire is a useful alternative. Our aim in this
study was to examine the predictive value of a self-report comorbidity questionnaire in terms of survival in ESRD patients.
Methods: We studied a prospective cross-sectional cohort of 282 haemodialysis (HD) patients in a single centre.
Participants were administered the self-report questionnaire during an HD session. Information on their comorbidities was
subsequently obtained from an examination of the patient’s medical records. Levels of agreement between parameters
derived from the questionnaire, and from the medical records, were examined. Participants were followed-up for 18
months to collect survival data. The influence on survival of comorbidity scores derived from the self-report data
(the Composite Self-report Comorbidity Score [CSCS]) and from medical records data - the Charlson Comorbidity Index
[CCI] were compared.
Results: The level of agreement between the self-report items and those obtained from medical records was almost
perfect with respect the presence of diabetes (Kappa score κ 0.97), substantial for heart disease and cancer (κ 0.62 and
κ 0.72 respectively), moderate for liver disease (κ 0.51), only fair for lung disease, arthritis, cerebrovascular disease, and
depression (κ 0.34, 0.35, 0.34 and 0.29 respectively). The CSCS was strongly predictive of survival in regression models
(Nagelkerke R2 value 0.202), with a predictive power similar to that of the CCI (Nagelkerke R2 value 0.211). The influences
of these two parameters were additive in the models – suggesting that these parameters make different contributions
to the assessment of comorbidity.
Conclusion: This self-report comorbidity questionnaire is a viable tool to collect comorbidity data and may have a role in
the prediction of short-term survival in patients with end-stage renal disease on haemodialysis. Further work is required in
this setting to refine the tool and define its role.
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Patients with end-stage renal disease (ESRD) often have
a number of comorbid conditions. Comorbidity is an im-
portant outcome measure in patients with ESRD and
has been shown to be a significant predictor of mortality
in this patient population [1-5]. Hence, obtaining infor-
mation on comorbid conditions is vital for clinical and
research purposes.
The Charlson Comorbidity Index (CCI) was developed
to predict patient survival using comorbidity data in longi-
tudinal studies [6]. The CCI has been shown to be a* Correspondence: sridharansivakumar@gmail.com
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unless otherwise stated.significant predictor of clinical outcomes in ESRD patients
[4,7]. CCI is calculated from information gathered from
medical records which is time-consuming. Moreover, data
collection may be limited by the ease of availability of the
records and the accuracy of the documentation of specific
medical conditions.
A simple, self-report questionnaire would be a useful al-
ternative tool for collecting comorbidity data. Self-report
questionnaires derived from the general population may
not be suitable for patient populations with specific
chronic diseases such as ESRD. It is important to define
the role of such questionnaires in disease-specific pa-
tient population. We developed a simple self-reportral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Sridharan et al. BMC Nephrology 2014, 15:134 Page 2 of 8
http://www.biomedcentral.com/1471-2369/15/134questionnaire to obtain comorbidity data from patients
with ESRD.
Our aim was to explore the level of agreement of the in-
formation obtained from the questionnaire and medical
records. We also wished to study the association between
the questionnaire-derived comorbidity score and short-
term survival and relate this to the performance of the
established Charlson Comorbidity Index (CCI).
Methods
Self-report questionnaire
The self-report comorbidity questionnaire (see Additional
file 1) was based on that developed by Sangha et al. [8].
This questionnaire has been validated in general medical
and surgical patients and had been shown to correlate
with subsequent health status and resource utilisation [8].
We chose eight conditions that are commonly prevalent
in patients with ESRD to include in the questionnaire.
The conditions were expressed in a plain language that
could be understood by individuals without any prior
medical knowledge. Also, participants had the option of
adding 3 additional medical conditions other than the
ones that were listed. The first 2 questionnaire items, both
enquired about cardiac disease, one relating to current
and the other past history. This enabled more complete
data capture regarding heart disease even in patients with-
out ongoing symptoms.
As all study participants had ESRD and were receiving
HD, we did not include the question about renal disease.
For each of the listed conditions and the additional ones
the participants could add, they were asked 3 questions –
whether they had the condition, if they did, whether they
were receiving any treatment and whether the disease was
limiting their activities. Participants were asked to tick the
respective box if the answer to the corresponding question
was in the affirmative. The questions regarding treatment
and limitation of activities served as a surrogate marker of
the severity of the illness. All participants completed the
questionnaire on their own without any help from health-
care staff.
The questionnaire was translated into Bengali and
Urdu to facilitate data capture from different ethnic pa-
tients who did not have sufficient knowledge of English to
complete the questionnaire. The translation was carried out
by Straker Translations (London, UK). Two independent
reviewers, who were native speakers of these languages,
verified the accuracy of the translations. Copies of the
translated versions of the questionnaire can be obtained by
contacting the corresponding author.
Scoring of the questionnaire
Each positive response had a score of 1. Hence, the max-
imum score was 3 for each medical condition – 1 for the
presence of the disease, 1 for being on treatment and 1 ifthe disease was limiting their activities. Of the listed con-
ditions, the first 2 referred to cardiac disease and were
considered as one item for purposes of scoring. A judge-
ment was made on the admissibility of the optional items
as significant comorbidities. In the event of the additional
items listed by patients (see later), we considered cerebro-
vascular disease (“stroke”) to be the only additional co-
morbidity with potential survival impact listed with
sufficient frequency to merit inclusion in the scoring. In
addition, since the level of agreement for depression be-
tween the questionnaire and the medical records was
poorest of all listed conditions (see later) and since depres-
sion did not contribute to any of the models tested, this
parameter was omitted from the scoring scheme. Hence
the Composite Self-report Comorbidity Score (CSCS) was
derived from 7 conditions – giving a potential maximum
of 21. Age was not included in this score.
Subjects and protocol
Ethical review
The study was approved by the North Wales Ethical Re-
view Committee. All subjects gave informed written
consent to take part.
Subjects
Patients on maintenance, in-centre HD were recruited
from the Renal units of East and North Hertfordshire
NHS Trust. The study included patients older than 18
years, dialysing 3 times a week and those able to under-
stand English, Bengali or Urdu to allow them to complete
the questionnaire. Exclusion criteria included patients
with no capacity to consent, those dialysing other than
3-times weekly and those with limb amputations.
Study protocol
Each participant was administered the questionnaire on at-
tendance for their regular HD session and asked to
complete it by the end of that session. The demographic in-
formation of the participants (age, sex, and ethnicity) and
their documented comorbidities were collected from our
renal database. Our electronic renal database is continu-
ously updated through inputs from clinician assessments
and regular patient reviews. The Charlson Comorbidity
Index (CCI) was calculated as previously described [6]. One
of the authors (JB) administered and collected the question-
naire from the participants. Data from the medical records
was extracted by one of the other authors (SS) without
prior knowledge of individual comorbidity scores of the
participants. All participants were followed-up for 18
months to obtain survival data.
Statistical analysis
Statistical analysis was carried out using SPSS® version 19
(SPSS Software, IBM Corporation, Armonk, New York,
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SD, and non-normally distributed as median (interquartile
range [IQR]). Correlations between scores were deter-
mined using the Spearman coefficient.
We assessed the agreement for individual items between
the questionnaire and medical-record derived CCI using
the inter-rater kappa (κ) statistic [9]. We also calculated
the overall agreement, defined as the number of cases in
which both the patient responses and medical records
agreed (both “yes” and “no” responses) divided by the total
number of cases.
We used Logistic regression models to identify inde-
pendent predictors of survival in the study population. All
models included age, sex, and ethnicity as variables. Indi-
vidual patient-reported comorbid conditions that were sig-
nificantly associated with survival were identified, as well
as the contribution of the Composite Self-report Score
(CSCS) and the CCI.
We constructed Receiver Operator Curves (ROC) to
compare the utility of the CSCS and the CCI in predicting
mortality as well as defining the optimal cut-off points for
this prediction for both these scales. We compared the
levels of agreement for the cut-off point in the scales using
the inter-rater κ statistic [9]. In addition we compared the
predictive power of these cut-off points in predicting mor-
tality in Cox Regression models.Results
A total of 282 patients were recruited out of 350 haemodi-
alysis patients in our unit over a period of 1 month. There
were 177 males (62.8%). The mean age was 64.1 ± 15.3
years. The ethnic make-up was 201 white (71.3%), 51
South Asian (18.1%) and 30 black (10.6%) patients. For
the open-ended questions, 46 patients (16.3%) indicated 1
additional disease, 10 patients (3.5%) indicated 2 dis-
eases and 1 patient indicated 3 diseases. Frequently
mentioned additional diseases included hypertensionTable 1 Prevalence and levels of agreement of comorbid con
and medical records
Prevalence (%)
Records Self-report Limitin
Diabetes 84 (29.8) 82 (29.1) 22 (7.8
Heart disease 98 (34.8) 92 (32.6) 37 (13.
Cancer 20 (7.1) 18 (6.4) 3 (1.1
Liver disease 12 (4.3) 7 (2.5) 3 (1.1
Arthritis 22 (7.8) 72 (25.5) 47 (16.
Lung disease 29 (10.3) 13 (4.6) 8 (2.8
Cerebrovascular disease 10 (3.5) 22 (7.8) 2 (0.7
Depression 17 (6.0) 35 (12.4) 15 (5.3
Variables considered were Age, Sex, Ethnicity, the presence of self-report Heart dise
and Arthritis.(11), stroke (10), hypothyroidism (5), visual impairment
(5), and peripheral vascular disease (2). Of these only
stroke was considered as significant additional comorbid-
ity as discussed earlier. Hypertension was not included
since this is a feature of chronic kidney disease and
present in a very high proportion of patients on haemodi-
alysis and Peripheral vascular disease since it was listed
only twice. The other conditions mentioned by patients
were hearing loss, back pain, inguinal hernia, insomnia,
lymphoedema, gout, glaucoma and diverticulitis.Level of agreement
Table 1 shows the prevalence of each item as determined
from the medical records and the comorbidity question-
naire and the level of agreement between them. Prevalence
of heart disease, diabetes mellitus and cancer was similar
between the medical records and the questionnaire. The
prevalence of both lung and liver disease as obtained from
medical records was higher than the self-reported. For the
prevalence of arthritis and depression the opposite pre-
vailed. Overall agreement exceeded 80% for all items with
the highest agreement for diabetes mellitus (99%) and the
lowest for arthritis (81%).
Table 1 also shows the κ statistic and the interpretation
of the κ for each item. There was almost perfect agreement
between the two instruments for diabetes, substantial
agreement for heart disease and cancer, and moderate
agreement for liver disease. There was only fair agreement
for lung disease, arthritis, depression and cerebrovascular
disease. There was no association observed between gender
and agreement of patient self-reports with medical records
for any of the items listed. Using age as a dichotomous vari-
able (age less than 65 vs. 65 or more) in this analysis, we
found significant differences in level of agreement for arth-
ritis and depression. κ was significantly higher in older
patients for arthritis and in younger patients for depres-
sion (p = 0.03 for both).ditions according to Self-report comorbidity questionnaire
Level of
agreement (%)
Kappa (95% CI) Interpretation
of Kappag
) 99 0.97 (0.93, 1.00) Almost Perfect
1) 83 0.62 (0.52, 0.72) Substantial
) 96 0.72 (0.55, 0.89) Substantial
) 97 0.51 (0.20, 0.83) Moderate
7) 81 0.35 (0.09, 0.50) Fair
) 91 0.34 (0.10, 0.58) Fair
) 93 0.34 (0.09, 0.56) Fair
) 88 0.29 (0.06, 0.51) Fair
ase, Cerebrovascular disease, Cancer, Diabetes, Liver disease, Lung disease,
Figure 1 Histogram showing distribution of Composite Self-report Comorbidity Score (left hand panel) and Charlson Comorbidity
Index (right hand panel).
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The distributions of the CSCS and CCI are shown in
Figure 1. The median CSCS was 2 (IQR3). The median
CCI was 6 (IQR3). The CSCS correlated with the CCI
(rho = 0.531; p < 0.001).
Survival prediction
Of the 282 participants, 58 (20.6%) died in the 18
months following recruitment.
Logistic regression
Table 2 shows the best Logistic Regression Model for
predictors of survival at 18 months based on individual
self-report comorbid conditions (Hosmer and Lemeshow
Chi-square 11.115; p = 0.195: Nagelkerke R-square value
0.197). Variables considered were age, sex, ethnicity,
presence of self-report heart disease, cerebrovascular
disease, cancer, diabetes, liver disease, lung disease, and
arthritis. Heart disease, liver disease and arthritis, along
with age, were significant predictors of survival.
The logistic regression models for the CSCS and the
CCI are shown in Table 3. The models including these
individual parameters showed similar goodness of fitTable 2 The best Logistic Regression Model for
predictors of survival at 18 months based on individual
self-report comorbid conditions
B S.E. Wald p-value Exp(B)
Age .030 .013 5.287 .021 1.030
Heart disease 1.242 .319 15.124 .000 3.462
Liver disease 1.794 .856 4.392 .036 6.013
Arthritis .858 .334 6.582 .010 2.358
Constant −4.169 .902 21.374 .000 .015(Hosmer and Lemeshow Chi-square 4. 151 [p = 0.843]
and 1.878 [p = 0.985]) and predictive power (Nagelkerke
R-square values 0.202 and 0.211 respectively). Each par-
ameter had a highly statistically significant relationship
to survival within the models (p <0.001 in both cases).
Interestingly the model was improved by inclusion of
both parameters (Nagelkerke R-square 0.250) and in this
model (Table 3 – lower panel) both parameters retained
a high degree of statistical significance. This suggests
that each of these parameters contributes different as-
pects to the assessment of comorbidity.
Receiver Operator Characteristics (ROC) analysis
We constructed ROC curves to compare the performance
of CSCS and CCI in predicting death within the follow-up
period, and to determine the best cut-off values of both
these parameters for this prediction (Figure 2). The Area
under the Curve in ROC analysis was similar for these
parameters with overlapping 95% confidence intervals:
0.724 (0.651 – 0.797) and 0.754 (0.684 – 0.823) respect-
ively. The best cut-off points for predicting mortality
during the follow-up period were determined as CSCS >3
and CCI > 6. Patients with CSCS > 3 are subsequently re-
ferred to as having high CSCS. Likewise high CCI values
refer to CCI > 6.
Comparison of cut-off points of CSCS and CCI in mortality
prediction
Figure 3 compares the adjusted survival of patients
with high CSCS (69 patients) and those with high CCI
(94 patients). In both cases survival is adjusted for age,
sex and ethnicity in Cox Regression models. Both high
CSCS and high CCI were highly predictive of mortality
within their separate models (p < 0.001 in both cases).
Table 3 Logistic regression models for survival at 18 months
MODEL 1: Nagelkerke R2 = 0.202 B S.E. Wald p-value Exp(B)
Age (Years) .030 .013 5.540 .019 1.031
Sex (Male v Female) .440 .344 1.635 .201 1.553
Ethnicity (Non-white v White) -.222 .381 .340 .560 .801
CSCS .392 .081 23.386 .000 1.480
Constant −4.616 .962 23.026 .000 .010
MODEL 2: Nagelkerke R2 = 0.211
Age (Years) -.015 .016 .894 .344 .985
Sex (Male v Female) .211 .348 .367 .545 1.235
Ethnicity (Non-white v White) -.213 .376 .322 .570 .808
CCI .521 .105 24.445 .000 1.683
Constant −3.641 .909 16.035 .000 .026
MODEL 3: Nagelkerke R2 = 0.250
Age (Years) -.002 .016 .021 .886 .998
Sex (Male v Female) .298 .355 .702 .402 1.347
Ethnicity (Non-white v White) -.315 .387 .663 .416 .730
CCI .365 .117 9.715 .002 1.440
CSCS .262 .092 8.180 .004 1.300
Constant −4.251 .972 19.125 .000 .014
Model 1 includes the Composite Self-report Comorbidity Score (CSCS). Model 2 includes the Charlson Comorbidity Index (CCI). Model 3 includes both parameters.
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lapping 95% Confidence Intervals (4.050 [3.362 – 6.947]
and 4.139 [2.202 – 7.774] respectively). In spite of this,
when these parameters were included together in the
same Cox model, both retained their significance, andFigure 2 Receiver Operator Characteristic curves comparing
compare the performance of the Composite Self-report
Comorbidity Score and the Charlson Comorbidity Index in
predicting death within the follow-up period.Hazard Ratios of each were similar, approaching 3
(Table 4). This again suggests that each parameter contrib-
uted different elements to the assessment of comorbidity.
In keeping with this, the level of agreement between patient
with high CSCS and high CCI was only fair (κ = 0.325;
p < 0.001). The main difference between these high comor-
bidity groups relates to mean age which, unsurprisingly,
was significantly higher in the high CCI group than in the
high CSCS group (73.6 ± 8.7 vs. 67.4 ± 11.7; p <0.001).
There were other differences. The best levels of agreement
between CCI (high vs. low) and the presence or absence of
individual components of the CCI, were for heart disease (κ
0.447), diabetes (κ 0.443), cerebrovascular disease (κ
0.301) and cancer (κ 0.205). On the other hand the
best agreements between CSCS (high vs. low) and the
presence or absence of individual components of the
CSCS, were with heart disease (κ 0.491) and arthritis
(κ 0.442) and diabetes (κ 0.396).
Discussion
Information on comorbid conditions is essential in routine
clinical practice and also for research purposes. We have
designed a simple, self-report questionnaire to obtain co-
morbidity data in patients with advanced kidney failure,
receiving treatment by dialysis. The questionnaire-derived
comorbidity score – the CSCS – was significantly predict-
ive of short-term survival in this patient group and may
have clinical utility.
Figure 3 Adjusted Survival for patients with high comorbidity scores (Charlson Comorbidity Index > 6 – Left panel and Composite Self-report
Comorbidity Score > 3 – Right Panel). Each Cox Regression model also included Age, Sex and Ethnicity.
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ment between the prevalence of self-reported diabetes,
heart disease and cancer and the prevalence of these
conditions derived from the detailed examination of the
patients’ medical records. The level of agreement for
liver disease was moderate. For arthritis, lung disease,
cerebrovascular disease and depression the levels of
agreement were only fair. Whilst lung disease and cere-
brovascular disease were under-reported by patients,
arthritis and depression were reported more frequently
compared to the medical records. There are a number of
factors which may contribute to these discrepancies.
Our data suggests that even though lung disease was
under-reported in the questionnaire, a high proportion
of those patients who did report having this condition
indicated that their disease limited their activities. This
suggests that patients with milder forms of lung disease
may not attribute much significance to related symp-
toms (e.g. “smoker’s cough”) or may not be aware of the
diagnosis at all. The under-reporting of cerebrovascular
disease was almost certainly caused by the fact that thisTable 4 Cox model of predictors of short term survival in
haemodialysis patients
B S.E. Wald p-value Exp(B)
Age (Years) .011 .012 .840 .359 1.011
Sex (Male v Female) .405 .299 1.831 .176 1.500
Ethnicity (Non-white v White) -.411 .315 1.700 .192 .663
CCI > 6 1.020 .334 9.348 .002 2.773
CSCS > 3 1.067 .292 13.309 .000 2.907
The model contains both the Composite Self-report Comorbidity Score (CSCS)
and the Charlson Comorbidity Index (CCI).was not a condition specified on the questionnaire and pa-
tients wishing to report this condition had to write this in
under “other medical conditions”. The conditions which
were over-reported by patients, arthritis and depression,
are predominantly diagnosed and treated in primary care.
This may sometimes lead to their not being documented
in hospital records unless they are receiving medication
for that condition or if its severity warrants secondary care
referral. The poorest level of agreement was found with
depression and this, and its failure to contribute to any of
the survival models we considered, caused us to exclude
this parameter from contributing to the CSCS. Further-
more, though depression has been shown to be associated
with mortality in CKD population, the diagnosis of de-
pression in these studies has been made formally using
physician diagnosis, clinical coding, or validated self-
report screening tools, not by a single question in a
self-report questionnaire the response to which may
well just reflect subjects’ transient feelings.
We found that the CSCS was a significant predictor
of survival in haemodialysis patients. The main individ-
ual comorbid conditions contributing to this predictive
power in this patient group were the presence of heart
disease, liver disease and arthritis (Table 2).
We compared the power of the CSCS and the CCI in
predicting mortality over the 18 month follow-up period.
In logistic regression models which allowed adjustment for
age, sex and ethnicity, we found the parameters to have
similar predictive power (Table 3). Since the CCI includes a
term for age, such a modelling approach is required to
allow for this in the comparison. The ROC analysis also
showed that the parameters performed similarly in predict-
ing death within the follow-up period. The area under the
Sridharan et al. BMC Nephrology 2014, 15:134 Page 7 of 8
http://www.biomedcentral.com/1471-2369/15/134ROC curve was greater for CCI than for CSCS (0.754 vs.
0.724). This difference was not significant and is probably
accounted for by the fact that age is not controlled for in
this method of comparison.
We also used ROC analysis to help determine the best
cut-off points for the CSCS and CCI for predicting mor-
tality during follow-up. The high comorbidity groups were
determined as CSCS >3 and CCI > 6. The performances
of these parameters in predicting death were similar in
Cox Models, again controlling for age, sex and ethnicity
(Figure 3).
Interestingly the use of CSCS together with CCI in a
logistic regression model improved the model with both
terms retaining significant predictive power. The findings
were similar with the use of both high CSCS and high
CCI in a Cox Model. These findings, together with the
only fair level of agreement between high CSCS and high
CCI suggest that these parameters make different contri-
butions to the assessment of comorbidity. The obvious
difference relates to the inclusion of a contribution of
patient age in the calculation of CCI. Indeed we found
that high CCI group was significantly older than the high
CSCS group. There were other differences between these
two groups. Both were similarly influenced by their com-
ponents relating to heart disease, and diabetes but the
high CCI group was more influenced by components
relating to cerebrovascular disease and cancer, and the
high CSCS group by the component related to arthritis.
Instruments such as the CCI rely on availability and
accuracy of medical records and as such, may be limited in
its utility for clinical and research purposes. A self-report
comorbidity questionnaire can help collect this information
reliably and with relative ease. Various self-report health
measures have been previously studied in patients with
renal failure [10,11]. Our self-report questionnaire has the
advantage of being brief, easily understandable by patients
and at the same time being comprehensive enough to in-
clude commonly prevalent comorbid conditions in ESRD
patient population. Also, the questionnaire enquires about
the treatment and limitations imposed by specific diseases
which can be used as a surrogate marker of the severity
of the disease. The high levels of agreement between
the self-report and clinical records with respect to dia-
betes, heart disease and cancer suggests that the utility of
the self-report approach could embrace the collection of
such condition-specific data for inclusion in survival
models.
There are a number of limitations to our study. It has
been shown previously that medical records may in
themselves have substantial errors [12-14] and hence,
using this method as a “gold standard” may be less than
ideal. Also, with any questionnaire-based technique there
is a potential for recall bias. Though patients had the op-
tion of adding any additional diseases that were not listed,it is possible that patients may not recall milder forms of
existing comorbid diseases and this may exclude some
important comorbid conditions such as cerebrovascular
disease and peripheral vascular disease. Further devel-
opment of this questionnaire should include specific
enquiry about the presence and severity of these conditions.
Finally we have only examined the predictive capacity of
this self-report questionnaire with regards to short-term
survival in haemodialysis patients and as such, the results
should not be extrapolated to other groups of patients with
kidney disease, or to the assessment of long-term survival.
Conclusion
In summary, our self-report comorbidity questionnaire is
a simple and reliable tool for obtaining comorbidity data
in clinical practice and research studies involving patients
with end-stage renal disease on haemodialysis. There is
strong agreement between this self-report instrument and
data derived from medical records on important comorbid
conditions that have an influence on patient outcome.
The instrument also provides information on severity of
the comorbid diseases. In addition, the comorbidity score
generated (CSCS) has comparable predictive power for
short-term survival in haemodialysis patients to the CCI.
Further work is needed to adapt the questionnaire and to
examine its applicability in studies assessing long-term
survival and other clinical outcomes in patients with
kidney disease.
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